MISGAV, Israel & WAYNE, Pa.--(BUSINESS WIRE)--Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 23 December 2013, Dr. Andrew L. Pearlman, founder and a director, has established a personal stock trading plan in accordance both with the guidelines established by Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the AIM Rules for Companies as well as the Company’s policies with respect to insider sales.
Help employers find you! Check out all the jobs and post your resume.
